Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small mole...
Leadership
David A. Stamler M.D.
CEO & Director
Abby Macnish Niven B.Com., B.Sc., C.F.A.
CFO & Company Secretary
Rudolph Emile Tanzi Ph.D.
Chief Scientific Advisor and Member of Research & Development Advisory Board
